title: Sequential treatment of recurrent mesenteric desmoid tumor.
abstract: BACKGROUND
  The optimal management of inoperable desmoid tumors is still unclear. We report a 26 year-old female patient with familial adenomatous polyposis suffering from a recurrent inoperable intraabdominal desmoid tumor and its sequential treatment.
  
  
  METHODS
  Treatment strategies included low-dose tamoxifen (30 mg orally per day), high-dose tamoxifen (90 mg orally per day), and a subsequent combination of goserelin acetate (3.6 mg subcutaneously once every four weeks) plus low-dose tamoxifen, medroxyprogesterone acetate (1000 mg orally per day) and interferon gamma (3 Mio IU subcutaneously 3 times a week).
  
  
  RESULTS
  The combination of goserelin acetate and low-dose tamoxifen resulted in a decrease in tumour size and a complete relief of symptoms for 17 months. Thereafter the tumor progressed and again growth was stopped with interferon gamma therapy for another 6 months. All other treatment modalities had no effect.
  
  
  CONCLUSIONS
  This study demonstrates long-term regression of a desmoid tumor with combined endocrine therapy using goserelin acetate plus tamoxifen. Tumor progression after 17 months was again stopped by a combination of interferon-gamma and goserelin acetate.
authors.affiliation: Department of Internal Medicine, Division of Oncology, Karl Franzens University, Graz, Austria.
authors.forename: T
authors.initials: T
authors.lastname: Bauernhofer
authors.forename: H
authors.initials: H
authors.lastname: Stöger
authors.forename: M
authors.initials: M
authors.lastname: Schmid
authors.forename: M
authors.initials: M
authors.lastname: Smola
authors.forename: B
authors.initials: B
authors.lastname: Gürtl-Lackner
authors.forename: G
authors.initials: G
authors.lastname: Höfler
authors.forename: G
authors.initials: G
authors.lastname: Ranner
authors.forename: E
authors.initials: E
authors.lastname: Reisinger
authors.forename: H
authors.initials: H
authors.lastname: Samonigg
mesh_terms: D011125:Adenomatous Polyposis Coli / Q000473:pathology; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D018222:Desmoid Tumors / Q000000981:diagnostic imaging / Q000628:therapy*; D017273:Goserelin / Q000008:administration & dosage; D006801:Humans; D007371:Interferon-gamma / Q000008:administration & dosage; D008525:Medroxyprogesterone / Q000008:administration & dosage; D008643:Mesentery; D009364:Neoplasm Recurrence, Local; D009378:Neoplasms, Multiple Primary; D010534:Peritoneal Neoplasms / Q000000981:diagnostic imaging / Q000628:therapy*; D013629:Tamoxifen / Q000008:administration & dosage; D014057:Tomography, X-Ray Computed
chemical_list: D013629:Tamoxifen; D017273:Goserelin; D007371:Interferon-gamma; D008525:Medroxyprogesterone